Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vensobafusp alfa
- Development stage
- Unknown
- Lead developer
- Jasper Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Vensobafusp alfa (KP-104) is an investigational bifunctional biologic designed to simultaneously inhibit both the alternative and terminal pathways of the complement system. It is a recombinant fusion protein consisting of a humanized IgG4 monoclonal antibody targeting terminal complement protein C5, fused to the complement factor H (FH) domains 1-5. By targeting C5, the drug prevents the formation of the membrane attack complex (MAC), while the FH component provides targeted regulation of the alternative pathway C3 convertase. Developed by Kira Pharmaceuticals (which is merging with Jasper Therapeutics), vensobafusp alfa is being evaluated for the treatment of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN), and C3 glomerulopathy (C3G).
- Other names
- vensobafusp alfa
02
Targets
C5
Beyond the preview
Go deeper on vensobafusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vensobafusp alfa.